Boston Scientific reported a 12% year-over-year increase in international revenue for the fourth quarter of fiscal 2025, led by double-digit growth in Europe and Asia-Pacific. The company’s MedSurg business further expanded its global market share by 120 basis points, reaching 15.2% of the large-bore vascular access closure segment. Meanwhile, WATCHMAN device procedures rose 27% compared with the prior year, supported by new hospital contracts in Germany and Japan and an enhanced clinician training program that led to a 30% reduction in procedural complications.

On January 6, Boston Scientific shares moved decisively above their 50-day moving average following a 10% rally over the past two weeks, reversing a six-week downtrend. Trading volume on the breakout day surged 18% above the 60-day average, suggesting strong institutional buying. Technical analysts note that the stock also found support at its 200-day moving average near the end of December, establishing a floor that could underpin further gains if volume holds above 1.5 million shares daily.

Despite these positives, Boston Scientific faces potential headwinds from slowing hospital capital budgets in key Western markets and increased competition in interventional cardiology. Management has guided for mid-single-digit organic revenue growth in 2026, down from 8% in the prior year, and cautioned that reimbursement reforms in the U.S. could compress gross margins by up to 80 basis points. The company plans to mitigate these pressures through a 5% reduction in SG&A expenses, targeted R&D investments in next-generation drug-eluting stents, and the rollout of five new product launches across Europe and North America by year-end.